You just read:

Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine

News provided by

Amgen

Jun 08, 2016, 16:30 ET